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Abstract
Background: During the early stage of HIV-1 replication, integrase (IN) plays important roles at several steps,
including reverse transcription, viral DNA nuclear import, targeting viral DNA to host chromatin and integration.
Previous studies have demonstrated that HIV-1 IN interacts with a cellular Lens epithelium-derived growth factor
(LEDGF/p75) and that this viral/cellular interaction plays an important role for tethering HIV-1 preintegration
complexes (PICs) to transcriptionally active units of host chromatin. Meanwhile, other studies have revealed that
the efficient knockdown and/or knockout of LEDGF/p75 could not abolish HIV infection, suggesting a LEDGF/p75-
independent action of IN for viral DNA chromatin targeting and integration, even though the underlying
mechanism(s) is not fully understood.
Results: In this study, we performed site-directed mutagenic analysis at the C-terminal region of the IN catalytic
core domain responsible for IN/chromatin binding and IN/LEDGF/p75 interaction. The results showed that the IN
mutations H171A, L172A and EH170,1AA, located in the loop region 170EHLK173 between the a4 and a5 helices of
IN, severely impaired the interaction with LEDGF/p75 but were still able to bind chromatin. In addition, our
combined knockdown approach for LEDGF/p75 also failed to dissociate IN from chromatin. This suggests that IN
has a LEDGF/p75-independent determinant for host chromatin binding. Furthermore, a single-round HIV-1
replication assay showed that the viruses harboring IN mutants capable of LEDGF/p75-independent chromatin
binding still sustained a low level of infection, while the chromatin-binding defective mutant was non-infectious.
Conclusions: All of these data indicate that, even though the presence of LEDGF/p75 is important for a productive
HIV-1 replication, IN has the ability to bind chromatin in a LEDGF/p75-independent manner and sustains a low
level of HIV-1 infection. Hence, it is interesting to define the mechanism(s) underlying IN-mediated LEDGF/p75-
independent chromatin targeting, and further studies in this regard will help for a better understanding of the
molecular mechanism of chromatin targeting by IN during HIV-1 infection.
Background
The human immunodeficiency virus type 1 (HIV-1) pro-
tein integrase (IN) catalyzes the insertion of proviral
DNA into host chromosomes, a unique and obligatory
step for all retroviral infection. The integration of pro-
viral DNA is a two-step process involving 3’ processing
and 5’ strand transfer, which has been well characterized
by in vitro studies [1,2]. Integration occurs between a
large nucleoprotein complex, referred to as the preinte-
gration complex (PIC), and host chromatin. Neverthe-
less, how the PIC and chromatin interact within the
nucleus remains largely unknown. Shortly after viral
entry, the PIC formed in the host cellular cytoplasm is a
functional nucleoprotein complex in which newly
reverse transcribed viral DNAs are complexed with both
viral proteins, including IN, matrix (MA), nucleocapsid,
reverse transcriptase (RT), viral protein R (Vpr) and var-
ious cellular proteins (reviewed by Al-Mawsawi LQ
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any medium, provided the original work is properly cited.et al.) [3]. These cellular proteins include Lens epithe-
lium-derived growth factor (LEDGF), Integrase interac-
tor 1 (INi1), high-mobility group protein 1 (HMGA1),
barrier to auto-integration factor (BAF), Heat shock pro-
tein 60 (HSP60), Polycomb group embryonic ectoderm
development (EED) protein, etc. (for a review see [4]).
After nuclear import, PICs are targeted to the chromatin
until successful integration into one of the host
chromosomes.
As a functional component of PICs [5,6], the roles of
LEDGF or p75 during lentiviral DNA integration have
attracted increasing interest in recent years. LEDGF/p75,
discovered as a general transcriptional co-activator [7],
was isolated from a human lens epithelial cell (LEC)
cDNA library and named LEDGF by Singh DP et al. [8].
LEDGF/p75 interacts with IN by its Integrase Binding
Domain (IBD) (residues 341-429) [9,10]. The binding
sites for LEDGF/p75 in IN are mainly located within the
catalytic core domain (CCD) and around amino acids
W131, W132 and I161-E170 [9,11-13]. The LEDGF/p75
plays multiple roles during HIV-1 infection through
interaction with IN, such as protecting IN from protea-
somal degradation [5], potentially affecting the nuclear
transport of IN [5,14], stabilizing IN as a tetramer [15],
enhancing IN enzymatic activities [16,17] and, most
strikingly, serving as the IN-to-chromatin tethering fac-
tor driving PICs to transcriptionally active regions of
host chromosomes [5,14].
A number of previous studies have employed in vitro
biochemical approaches to study the interaction
between IN and DNA substrates by using oligonucleo-
tides that mimic the HIV LTR, and they have identified
several residues in the IN that are responsible for its
affinity for DNA [18-20]. All three domains of IN,
including the N-terminal domain (NTD), CCD and C-
terminal domain (CTD), have been shown to interact
with DNA by in vitro studies [21-23]. However, how IN
interacts with host chromatin under physiological con-
ditions is considerably less well understood. Recently, by
using a cell-based chromatin binding assay and co-
immunoprecipitation (co-IP), we have identified three
IN mutations (V165A, A179P, KR186,7AA) that
impaired binding to host chromatin and LEDGF/p75
[24]. According to recent reports by Berthoux [25] and
McKee et al. [15], the reduced affinity of IN
KR186,7AA for LEDGF/p75 is due to disabled oligomer-
ization of IN. As described previously, V165 is involved
in the IN/LEDGF/p75 interaction interface [11,12,26],
and A179 was identified as a new LEDGF/p75-binding
site. The structure of the IN CCD and LEDGF IBD
complex has been solved by a co-crystallization study
[9]. Moreover, a recent study revealed that the interac-
tion requires two asymmetric IN dimers and two
LEDGF/p75 molecules, which was determined by mass
spectrometry and cryo-electron microscopy [16]. How-
ever, both the architecture of the functional IN/LEDGF/
DNA complex as well as the way in which these two
proteins interact and work on both the viral DNA and
host chromatin in the process of integration remain elu-
sive. Further mutagenic analysis for IN/chromatin and
IN/LEDGF interactions may not only help to elucidate
the molecular mechanism of the IN/chromatin tethering
and binding but also facilitate the identification of
novel cellular factor(s) involved in this important viral
replication step.
In the present study, we investigated the interactions
of various IN mutants with host cell chromatin and
LEDGF/p75 by cell-based chromatin binding and co-IP
assays. In addition to previously described LEDGF/p75-
binding defective IN mutants V165A, A179P,
KR186,7AA [11,24,26], this study also identified several
new IN mutants, including K159P, V176A and I203P,
which reside in a4t oa6 helices of IN that lost the abil-
ity to bind to both chromatin and LEDGF/p75. Interest-
ingly, we also found that several IN mutations, H171A,
L172A and EH170,1AA, within the loop region
170EHLK173 of IN, impaired the interaction with
LEDGF/p75, but retained chromatin binding ability.
This suggests that the IN is able to bind chromatin
independently of LEDGF/p75. Consistently, our com-
bined knockdown approach for LEDGF/p75 also failed
to dissociate IN from chromatin. Moreover, we have
also tested the effect of these IN mutants on HIV-1
infection, and our results revealed that the viruses har-
boring the IN mutants incapable of binding chromatin
completely lost infectivity. However, viruses bearing IN
mutants with chromatin-binding ability still sustained
low levels of viral infection. All of these results clearly
indicated that while the LEDGF/p75-binding ability of
IN is important for productive HIV-1 replication, the IN
has the ability to bind chromatin in a LEDGF/p75-inde-
pendent manner and is sufficient to sustain a low level
of HIV-1 infection.
Materials and methods
Cell lines and transfection
Human embryonic kidney 293T and the African green
monkey kidney COS-7 cell lines were cultured in Dul-
becco’s Modified Eagles Medium (DMEM) supplemen-
ted with 10% fetal calf serum (FCS) and 1% penicillin-
streptomycin. Human CD4+ C8166 T-lymphoid cells
were maintained in RPMI-1640 medium supplemented
with 10% FCS and 1% penicillin-streptomycin. For trans-
fection of 293T cells and COS-7 cells, the standard cal-
cium phosphate precipitation technique, was used as
described previously [27].
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For chromatin binding, co-IP and immunofluorescence
assay, various CMV-YFP-IN mutants including
EH170,1AA, EK170,3AA, HL171,2AA and HK171,3AA
were constructed by PCR-based site-directed mutagen-
esis. The nucleotide sequences of the sense mutagenic
oligonucleotides are as follows: EH170,1AA, sense, 5’-
AGATCAGGCTGCTGCTCTTAAGAC-3’; EK170,3AA,
sense, 5’-GATCAGGCTGCACATCTTGCGACAG-
CAGT-3’; HL171,2AA, sense, 5’-AGGCTGAAGCTGC-
TAAGACAGC-3’;H K 1 7 1 , 3 A A ,s e n s e ,5 ’-
AGGCTGAAGCTCTTGCGACAGCAGTAC-3’.T h e
amplified HIV-1 IN fragment was cloned in-frame at
the 3’ end of the EYFP cDNA in a pEYFP-C1 vector
(Clontech) at BglII and BamH1 sites. To construct
pAcGFP-INwt/mut, each of the INwt/mut coding
sequences was subcloned into pAcGFP1-C vector (Clon-
tech) in-frame with the AcGFP coding sequence at BglII
and BamH1 restriction sites. LEDGF/p75 was cloned
into the pProLabel vector in-frame downstream of the
ProLabel tag named pProLabel-LEDGF. SVCMVin-T7-
LEDGF and the RT/IN/Env gene-deleted provirus
(NL4.3Luc/ΔBg/ΔRI) were previously described [24,28].
To test the effect of different IN mutants on viral infec-
tion, cDNAs encoding for IN mutants, including
EH170,1AA, EK170,3AA and HL171,2AA, were intro-
duced into the SVCMV-Vpr-RT-IN expression plasmid
by PCR-based method as described before [28].
Antibodies used for the immunofluorescence assay,
immunoprecipitation or WB are as followed: the mouse
monoclonal anti-b-Actin antibody (Abcam Inc.), rabbit
anti-LEDGF/p75 (Bethyl Laboratories, Inc.) and anti-T7
monoclonal antibodies (Novagen), and a highly purified
anti-GFP IgG fraction (through ion-exchange chromato-
graphy) purchased from Invitrogen Inc. (Cat. No. A6455)
were used as primary antibodies. FITC-conjugated anti-
rabbit antibody (Kirkegaard & Perry Laboratories (KPL)),
anti-mouse (GE healthcare) and anti-rabbit HRP-conju-
gated antibodies (Amersham Biosciences) were used as
the secondary antibodies.
Chromatin binding assay
After transfection of YFP-INwt/mut into 293T cells for
48 h, the association of HIV-1 IN with cellular chroma-
tin in mammalian cells was analyzed by a chromatin-
binding assay [5,24]. To simplify the assay, only S1
(non-chromatin-bound) and S2 (chromatin-bound) frac-
tions were analyzed by immunoprecipitation using an
anti-GFP antibody and detected by WB with the same
antibody. Protein bands in each fraction were further
quantified with the software Quantity One (Bio-Rad),
and the values are expressed as a percentage of chroma-
tin-bound YFP-IN to total input, which consists of YFP-
IN present in both S1 and S2.
Immunofluorescence assay
COS-7 cells or 293T cells were grown on glass cover
slips (12 mm
2) in 24-well plates for 24 h and then trans-
fected with different IN expression plasmids CMV-YFP-
INwt/mut. After 48 h of transfection, cells on the cover
slip were fixed and permeabilized for 30 min in metha-
nol/acetone (1:1 ratio) at room temperature. Then, glass
cover slips were incubated with primary rabbit anti-GFP
antibody followed by secondary FITC-conjugated anti-
rabbit antibody, and nuclei were stained with DAPI.
Cells were visualized by a Carl Zeiss microscope (Axio-
vert 200) with a 63× oil immersion objective. To obtain
the clearly defined intracellular localization of each YFP-
INwt/mut, we adjusted the parameters of the imaging
system for the best image of YFP-IN in glass slides.
Co-immunoprecipitation assay and chemiluminescent
co-immunoprecipitation (co-IP) assay
To detect the interaction between YFP-IN wt/mut and
T7-LEDGF, the co-immunoprecipitation assay was car-
ried out essentially as reported [24], except for modifica-
tions to the detection of the total input of YFP-IN and
T7-LEDGF expression. Briefly, YFP, wild type YFP-IN
or each YFP-IN mutant was co-transfected with T7-
LEDGF into 293T cells for 48 h. The transfected cells
were collected, and 90% of the cells were lysed in 0.25%
NP-40 in 199 buffer supplemented with a cocktail of
protease inhibitors and clarified by centrifugation at
13,000 rpm for 30 min at 4°C. The supernatant was sub-
sequently subjected to IP with a rabbit anti-GFP anti-
body. The bound proteins were detected by WB using
anti-T7 antibody. Meanwhile, 10% of transfected cells
were lysed in 0.5% NP-40, and the lysates were used to
detect the expression of YFP-INwt/mut and T7-LEDGF/
p75 by WB using anti-GFP and anti-LEDGF antibodies,
respectively.
The chemiluminescent co-IP assay was performed
according to manufacturer’s instructions. After AcGFP1-
INwt/mut or AcGFP1-C and ProLabel-LEDGF fusion
protein expression plasmids were co-transfected in 293T
cells for 48 h, the cells were collected and lysed in
0.25% NP-40 lysis buffer and co-immunoprecipitated
with Anti-GFP polyclonal antibody. For ProLabel detec-
tion of protein-protein interaction, the immunoprecipi-
tates were resuspended in lysis/complementation buffer
and transferred to a well in a 96-well assay plate
(Costar, Corning, NY). To each well, the substrate mix
was added, and ProLabel activity was measured using
the POLARstar OPTIMA multidetection microplate
reader (BMG Labtech).
Transient knockdown of LEDGF/p75 in 293T cells
Duplex stealth RNA interference (RNAi) for LEDGF
and scrambled RNAi were purchased from Invitrogen.
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5 293T cells were seeded per well in a 6-well plate
for 24 h and then cells were transfected with 20 nM
siRNA oligonucleotides (Stealth RNAi; Invitrogen) direc-
ted against PSIP1/LEDGF/p75 mRNA using Lipofecta-
mine 2000 (Invitrogen). Synthetic siRNA was designed
with the following target and sequence:
PSIP1HSS146003, targeting nucleotides 541 to 565
(5’UAAUGAAGGUUUAUGGGAGAUAGAU3’). In par-
allel, a scramble siRNA was used as negative control.
The efficiency of LEDGF knockdown was monitored by
WB at different time points (48 h, 72 h, 96 h, 120 h).
The production and transduction of lentivirus vector
containing LEDGF shRNA
To produce stable LEDGF/p75 gene knockdown 293T
cell lines, the pLKO.1 lentiviral vector comprising siRNA
hairpin targeting nucleotides of LEDGF/p75 mRNA was
purchased from Open Biosystems. The hairpin structure
contains a 21-bp stem, 5-nt loops, and 5’ CCGG and 3’
TTTTTG overhangs. The shRNA sequence RHS3979-
97063117 targets the corresponding LEDGF/p75 mRNA
nucleotides 860-880, and its stem-loop sequence was
CCGGGCAGCTACAGAAGTCAAGATTCTCGAGAA
TCTTGACTTCTGTAGCTGCTTTTTG. The lentiviral
particles harboring LEDGF/p75 shRNA were produced
by co-transfecting the shRNA pLKO.1 vector, packaging
DNA plasmid Δ8.2 and vesicular stomatitis virus G
(VSVG) plasmid into 293T cells. After 48 h, supernatants
containing lentiviral vectors were pelleted by ultracentri-
fugation (32,000 rpm at 4°C for 1 h) and stored in ali-
quots at -80°C.
To obtain stable LEDGF shRNA expressing cell lines,
293T cells were transduced with the shRNA LEDGF
lentiviral vector for 48 h and then selected with 2 μg/
mL puromycin for one week. Silencing of LEDGF/p75
was determined by WB analysis with an anti-LEDGF
antibody. Detection of endogenous beta-actin was used
for normalization of sample loading.
Virus Production and Infection
A VSV-G pseudotyped single-cycle replicating virus
was produced in 293T cells as described previously
[24,28]. Briefly, 293T cells were co-transfected with an
RT/IN/Env-deleted HIV-1 provirus NLlucΔBglΔRI,
each CMV-Vpr-RT-IN (wt/mutant) expression plasmid
and a VSV-G expression plasmid. After 48 h of trans-
fection, viruses were collected and concentrated from
the supernatants by ultracentrifugation at 35,000 RPM
for 2 h. Virus titers were quantified using HIV-1 p24
Antigen Capture Assay Kit (purchased from the NCI-
Frederick AIDS Vaccine Program). Equal amounts of
viruses (adjusted by virion-associated p24 levels) were
used to infect C8166 T cells overnight at 37°C. At 48 h
post-infection, 1 × 10
6 cells from each sample were col-
lected and lysed with 50 μL of luciferase lysis buffer
(Fisher Scientific Inc). A 10 μL aliquot of cell lysate was
subjected to the luciferase assay by using a POLARstar
OPTIMA (BMG LABTECH, Germany), and the lucifer-
ase activity was valued as relative light units (RLU).
Measurement of reverse transcription by quantitative
PCR analysis
After production of the VSV-G pseudotyped single-cycle
replicating viruses, equal amounts of virus (adjusted by
virion-associated p24 levels) were treated with 340 IU/
mL DNase (Roche Molecular Biochemicals) for 1 h at
37°C to remove residual plasmid DNA and then used to
infect C8166 CD4+ T cells. For negative control (NC),
prior to DNase treatment, wt virus was inactivated by
incubating at 70°C for 0.5 h. The DNA was isolated
from 1 × 10
6 C8166T cells at 12 h post-infection using
QIAamp® DNA blood kit (Qiagen sciences, Maryland,
USA) following the manufacturer’s instruction. The
reverse transcription activity of HIV-1 in the infected
cells was analyzed by quantifying the total HIV cDNA
by using the qPCR technique. The qPCR was performed
on Mx3000P detection system (Stratagene, CA) using
LightCycler FastStart DNA Master SYBR Green I master
mix (Roche diagnostics, Germany) along with forward
(5’-tac tga cgc tct cgc acc-3’) and reverse (5’-tct cga cgc
agg act cg-3’) primers targeted to the 5’ end of the LTR
and Gag region of the HIV-1 Bru genome [29]. The
optimized thermal conditions used in the qPCR were as
follows: initial hot start (95°C for 15 min) followed by
35 to 40 cycles of denaturation (94°C for 30 s), primer
annealing (60°C for 30 s) and extension (72°C for 1
min). The total HIV-1 cDNA levels were expressed as
copy numbers per cell, with DNA template normalized
by the b-globin gene.
Results
Analysis of different HIV-1 IN mutants for their
chromatin- and LEDGF/p75-binding
Our previous study showed that three IN CCD mutants
V165A, A179P, KR186,7AA, which cannot bind LEDGF/
p75, lack the ability to bind to host chromatin [24]. In
the present study, we carried out a detailed mutagenic
analysis to define binding site(s) for chromatin and
LEDGF/p75 within the CCD of IN. Besides the pre-
viously reported IN mutants, V165A, A179P,
KR186,7AA and a class I mutant D64/D116AA [24],
several new YFP-IN mutants were generated by site-
directed mutagenesis. The region E170-K173 was of
interest because it overlaps with a-helices 4/5 connector
residues 166-171 residing at the IN-LEDGF crystal
interface [9]. Meanwhile, the mutagenic studies have
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LK172,3AA for LEDGF/p75 interaction [11,12,26]. The
mutants K136, K159 were also included as they were
reported to be involved in IN/nucleotide binding
[30-32]. To address the role of a-helix 6 of IN in chro-
matin- and LEDGF interaction, mutants I200 and I203
were also included in the study. Table 1 lists 17 IN
amino acid residues analyzed in the study, their conser-
vations in different HIV-1 isolates, (the HIV sequences
database was downloaded from the LANL website
http://www.lanl.gov and aligned with MEGA4 program)
and mutations introduced for each residue(s).
These IN mutants were further subjected to the chro-
matin binding assay [24,33,34] to study their host chro-
matin binding ability. Briefly, each of YFP-INwt/mut
was transfected into 293T cells, and, after 48 h, the pre-
sence of each YFP-INwt/mut in chromatin- and non-
chromatin-bound fractions were analyzed by western
blot with anti-GFP antibody, as described previously
[24]. Our data showed that, in addition to the previously
described IN mutants (V165A, A179P, KR186,7AA [24])
K159P, V176A, A179I, I203P were also severely
impaired for host chromatin binding (Fig. 1A, data not
shown for A179I). By contrast, mutants K136A, H171A,
L172A, I182A and I203A were still able to associate
with chromatin. The chromatin binding affinity of
F185A and I200A was reduced by approximately 60% of
wild type IN (Fig. 1A).
Because LEDGF/p75 has been shown to be involved in
IN chromatin targeting, we also tested the LEDGF/p75-
binding ability of different IN mutants by a cell-based
co-IP assay. Equal amounts of T7-LEDGF and CMV-
YFP-IN wt/mut plasmids were co-transfected into 293T
cells. After 48 h of transfection, IN/LEDGF/p75 interac-
tion was analyzed by co-IP of YFP-IN with anti-GFP
antibody followed by Western blot (WB) with anti-T7
antibody. Results revealed a strong interaction between
T7-LEDGF and YFP-IN wild type and mutants D64E/
D116A, K136A, I182A, F185A, I203A. Meanwhile, the
mutants K159P, H171A, and I200A showed reduced
affinity for LEDGF/p75 (Fig. 2A, lanes 4, 6, and 13).
Interestingly, several IN mutants including V165A,
L172A, V176A, A179P, KR186,7AA, I203P lost their
interaction with LEDGF (Fig. 2A. lanes 5, 7, 8, 9, 12,
and 15). As expected, no T7-LEDGF/p75 was pulled
down by YFP control (Fig. 2A, lane 1). To ensure that
similar amounts of T7-LEDGF/p75 and YFP-IN were
expressed in each sample, the presence of T7-LEDGF/
p75 and YFP-IN in each sample was detected by WB
with corresponding antibodies (Fig. 2A, middle and
lower panel). The host chromatin and LEDGF/p75
cofactor interaction data of all the IN mutants analyzed
in this study have been summarized in Table 1. Interest-
ingly, we noted that IN mutants, H171A and L172A,
displayed a drastically reduced interaction with LEDGF/
p75 but still retained the interaction with chromatin.
Table 1 Summary of IN mutant chromatin/LEDGF binding phenotypes
Conservations * Mutations Chromatin binding Interaction with LEDGF/p75
Wild type Wild type +++ +++
D64/D116 99.4/99.7 DD64, 116EA +++ ++
K136 31.3 K136A +++ ++
K159 99.5 K159P - +/-
V165 93.5 V165A - -
E170 99.6 H171A +++ -
H171 98.5 L172A +++ -
L172 99.4 EH170,1AA ++ -
K173 96.9 EK170,3AA +++ +++
V176 99.4 HL171,2AA - -
A179 99.8 HK171,3AA ++ ++
I182 98.0 V176A - -
F185 99.4 A179P - -
KR186,7 99.7/99.0 A179I - NA
I200 98.3 I182A + ++
I203 96.8 F185A + ++
KR186,7AA - -
I200A + -
I203A +++ ++
I203P - -
* Percent identify at that position among a collection of 1242 HIV-1 and SIVcpz strains http://www.hiv.lanl.gov.
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mutants within Loop 170EHLK173
Interestingly, two IN mutants, H171A and L172A, that
showed differential binding abilities to chromatin and to
LEDGF/p75 are located in the CCD loop region
170EHLK173 of IN, a connector that links helices a4a n d
a5. Thus, we then focused our studies on this region,
which may be important for LEDGF/p75-binding, but
not for IN chromatin-association. Indeed, this region
overlaps with the interface for LEDGF-binding in the
crystal study [9], and some IN mutants within this
region, such as E170A, H171A, and LK172,3AA, have
been shown to be impaired in the ability to bind
LEDGF/p75 [11,12,26]. To further elucidate the func-
tional roles of loop 170EHLK173 on its chromatin and
LEDGF-binding, we characterized the binding affinities
of this region by testing the double mutants YFP-IN
EH170,1AA, HL171,2AA, EK170,3AA and HK171,3AA
(Fig. 3A). The chromatin-association experiment showed
that three of the double mutants EH170,1AA,
EK170,3AA and HK171,3AA displayed strong binding
affinity with cellular chromatin, whereas HL171,2AA
completely lost its chromatin binding ability (Fig. 3B).
Meanwhile, the LEDGF/p75-binding ability of each
mutant was also tested by co-IP assay, and results
showed that all the mutants except YFP-IN EK170,3AA
lost their ability to interact with LEDGF/p75 (Fig. 3C).
The differential LEDGF-binding abilities of these four
IN double mutants were re-confirmed by chemilumines-
cent co-IP assay (Fig. 3D). Altogether, uncoupled chro-
matin- and LEDGF-binding affinities were observed for
IN mutants H171A, L172A and EK170,1AA, with strong
binding affinity to chromatin but dramatically impaired
contact with LEDGF/p75.
Figure 1 Identification of chromatin binding sites within IN CCD. A). 293T cells were transfected with different CMV-YFP-IN expressors
(including the wild type IN and different mutants, as indicated). At 48 h post-transfection, cells were fractionated into chromatin-bound (lower
panel) and non-chromatin-bound (upper panel) fractions as described in Materials and methods. YFP-IN in each fraction was analyzed by IP and
WB with anti-GFP antibody. B). The intensity of both the chromatin-bound and non-chromatin-bound YFP-IN was densitometrically determined.
The data are presented as the percentage of chromatin-bound YFP-IN to total input. Results are representative of two independent experiments.
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Since HIV-1 IN has been shown to be a karyophilic pro-
tein and is involved in nuclear import of PICs, we won-
dered whether introducing mutations in the 170EHLK173
region of IN might interfere with IN nuclear transloca-
tion, which consequently affects their association with
chromatin and/or LEDGF/p75 binding. To address this
question, we transfected each IN mutant into COS-7
cells and analyzed their intracellular localization by
immunofluorescence. Given the low expression of the
YFP-IN fusion protein in COS-7 cells, the indirect
immunofluorescence technique was used (as described
in Materials and Methods). Results showed that, while
the wild type IN was localized in the nucleus, the IN C-
terminal deletion mutant YFP-IN1-212 was excluded
from the nucleus, consistent with previous studies
[24,28]. Also, all the IN 170EHLK173 region mutants,
including EH170,1AA, HL171,2AA, EK170,3AA and
HK171,3AA, were able to accumulate predominantly in
the nucleus (Fig. 4). All of these results indicate that 1)
the 170EHLK173 region is dispensable for IN nuclear
localization; and 2) the LEDGF/p75- and/or the chroma-
tin-binding defects of those IN mutants were not due to
their impaired nuclear translocation.
Figure 2 Identification of LEDGF/p75-binding sites within IN CCD. A). The CMV-YFP-INwt/mut or CMV-YFP plasmid was co-transfected with
SVCMVin-T7-LEDGF expressor in 293T cells. After 48 h of transfection, 90% cells were lysed and subjected to co-IP assay. The IN bound T7-
LEDGF/p75 was precipitated by using rabbit anti-GFP antibody and detected by WB using mouse anti-T7 antibody (upper panel). 10% cells were
lysed with 0.5% NP-40, directly loaded on 10% SDS-PAGE gel and probed with anti-T7 or anti-GFP antibody to detect T7-LEDGF or YFP-IN
expression (middle or lower panel). B). The intensity of protein bands was densitometrically determined. Results were expressed as the ratio of
bound T7-LEDGF/p75 expression (mutants/wild-type) which was normalized by total input. Binding affinity to LEDGF/p75 of YFP-IN wild type
was arbitrarily set as 100%. Results are representative of two independent experiments.
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chromatin binding
Uncoupled chromatin- and LEDGF-binding affinities
observed in IN mutants within the 170EHLK173 region
suggest that LEDGF/p75 may not be essential for IN
b i n d i n gt oc h r o m a t i n .T og a i nm o r ei n s i g h ti n t ot h e
association between IN chromatin binding and IN/
LEDGF interaction, we tested the effect of LEDGF/p75
knockdown (LEDGF/p75-KD) on IN chromatin binding
affinity. To obtain high efficiency gene knockdown, both
synthetic small interfering RNAs (siRNAs) and short
hairpin RNAs (shRNAs) were combined in the study to
knockdown LEDGF/p75 expression in 293T cells, as
described in Materials and Methods. The results showed
that such combined transient and stable LEDGF/p75-
KD resulted in over 90% reduction of LEDGF/p75
expression (Fig. 5B, lower panel). Then, the nuclear
localization of HIV-1 IN in LEDGF/p75-KD cells was
Figure 3 Differential effects of IN mutations within 170EHLK173 region on chromatin- and LEDGF-binding. A). Diagram of amino acids
sequence and introduced mutations in HIV-1 IN 170EHLK173 domain. B). Chromatin binding profiles of IN double mutants within 170EHLK173. 293T
cells were mock-transfected or transfected with equal amount of CMV-YFP-IN wild type or double mutants EH170,1AA, EK 170,3AA, HL171,2AA
and HK171,3AA. At 48 h post-transfection, cells were fractionated into chromatin-bound and non-chromatin-bound fractions as described in
Materials and methods. YFP-IN in each fraction was analyzed by IP and WB with anti-GFP antibody. Chromatin binding affinity was quantified by
laser densitometry and results are shown as the percentage of chromatin-bound to total input of YFP-IN (lower panel). C) LEDGF-binding affinity
within IN 170EHLK173 by co-IP assay. 293T cells were co-transfected with the SVCMVin-T7-LEDGF/p75 expressor and CMV-YFP-INwt/mut plasmid as
indicated. After 48 h of transfection, 90% of cells were lysed and subjected to co-IP assay as described before. The upper panel showed the
bound T7-LEDGF/p75 in each sample. 10% of cell lysates were used to detect the expression of YFP-INwt/mut and T7-LEDGF/p75 by WB using
anti-GFP and anti-LEDGF antibodies respectively (middle panel and lower panel). D). LEDGF-binding affinity within IN 170EHLK173 detected by
chemiluminescent co-IP assay. AcGFP1-INwt/mut or AcGFP1-C and ProLabel-LEDGF fusion proteins were coexpressed in 293T cells. After 48 h of
transfection, cells were lysed and immunoprecipitated with anti-GFP antibody and the chemiluminescent signals from ProLabel-LEDGF present in
the complexes were measured by using ProLabel Detection Kit II and valued as relative luminescence units (RLU). Results are representative of
two independent experiments.
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Page 8 of 14analyzed by indirect fluorescence using anti-LEDGF
antibody. As shown in figure 5A (lower panel), control
cells transfected with scramble siRNA displayed abun-
dant LEDGF/p75 protein expression. However, only a
trace amount of LEDGF/p75 was detected in 293T cells
transiently transfected with siRNA. Then, the cells were
stained with anti-GFP antibody to visualize the localiza-
tion of IN. Results showed that the wild type YFP-IN in
transient LEDGF/p75-KD cells still accumulated in
nuclei, suggesting that the LEDGF/p75-KD did not exert
any significant effect on IN nuclear localization (Fig. 5A,
upper panel).
Next, we checked whether LEDGF/p75 depletion has
an effect on IN chromatin binding. To do so, the
LEDGF/p75-KD 293T cells were transfected with YFP-
INwt, and after 24 h of transfection, cells were treated
with MG-132, a proteasome inhibitor, to prevent IN
degradation. Cells were processed for IN chromatin
binding analysis at 48 h post transfection, as described
above. Of note, no significant difference in the IN chro-
matin association was observed between the LEDGF/p75
KD cell line and the mock-transfected cell control (Fig.
5B, upper panel). In parallel, the 293T cells transfected
with the YFP-IN V165A mutant, which has been shown
to be defective of chromatin binding, was used as a
negative control [24]. Thus, our results demonstrated
that the LEDGF/p75 KD could not abrogate IN chroma-
tin binding.
Effect of IN 170EHLK173 mutants on HIV-1 infection
From the above results, we observed that LEDGF/p75
may not be mandatory for IN targeting to host chroma-
tin. However, we still do not know whether LEDGF/p75
independent chromatin binding of IN could ensure HIV
infection. To address this question, we introduced IN
double mutants EH170,1AA, EK170,3AA, and
HL171,2AA into an HIV-1 RT/IN trans-complemented
single cycle replication system [24,35]. Briefly, each of
these IN double mutants was first introduced into a
CMV-Vpr-RT-IN expression plasmid. The VSV-G pseu-
dotyped HIV-1 single cycle replicating viruses contain-
ing these individual IN double mutants and a luciferase
gene, substituted for the Nef gene, were produced in
293T cells by co-transfecting each CMV-Vpr-RT-INwt/
mut expression plasmid with RT/IN-deleted HIV pro-
virus NLlucΔ Bgl/ΔRI, and a VSV-G expression plasmid.
Then, the same amount of virus (normalized by p24 gag
levels) was used to infect C8166 CD4+ T cells, and the
level of infection was monitored by measuring the luci-
ferase activity. The results showed that the mutant
Figure 4 Subcellular localization of IN 170EHLK173 mutants in COS-7 cells. COS-7 cells were transfected with different CMV-YFP-IN fusion
protein expressors as indicated for 48 h. After fixation and permeabilization, cells were incubated with primary rabbit anti-GFP antibody followed
by secondary FITC-conjugated anti-rabbit antibodies, and the nuclei were stained with DAPI. Cells were visualized by a Carl Zeiss microscopy
(Axiovert 200) with a 63× oil immersion objective.
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Page 9 of 14EK170,3AA, which can efficiently bind to both chroma-
tin and LEDGF/p75, displayed about 30% replication
capacity relative to the wild type virus (Fig. 6A). The
chromatin-bound but LEDGF interaction defective IN
mutant virus, EH170,1AA, induced a low level of infec-
tion, whereas the HL171,2AA mutant virus, which lost
the ability to interact with both chromatin and LEDGF/
p75, was non-infectious (Fig. 6A). Moreover, real time
PCR analysis indicated that mutations introduced in the
170EHLK173 did not significantly affect the reverse tran-
scription step at 12 h post-infection (Fig. 6B). These
data suggest that while IN/LEDGF/p75 interaction is
important for a productive HIV-1 replication, the IN-
mediated LEDGF/p75-independent chromatin binding is
still able to sustain a low level viral infection.
Discussion
While the interaction between IN and viral DNA
was extensively investigated by in vitro studies
[18,19,22,36-39], less was known for IN interaction with
host chromatin under physiological conditions. Interest-
ingly, a large number of recent studies have demon-
strated that the cellular factor LEDGF/p75 plays an
important role in tethering HIV-1 IN to the transcrip-
tionally active units of host chromatin [40,41]. However,
how IN alone, in the absence of LEDGF/p75, plays a
role in chromatin binding needs to be fully understood.
In this study, we performed site-directed mutagenic ana-
lysis at the C-terminal region of the IN CCD for IN/
chromatin binding and IN/LEDGF/p75 interaction.
Results showed that several IN mutants including
K159P, V165A, V176A, A179P, KR186,7AA and I203P
were unable to bind both LEDGF/p75 and host chroma-
tin. The mutants H171A, L172A and EH170,1AA,
located in a loop region 170EHLK173 of IN, severely
impaired their interaction with LEDGF/p75 but were
still able to bind chromatin. Also, our data showed that
LEDGF/p75 depletion in cells failed to dissociate IN
Figure 5 LEDGF/p75 is not required for chromatin binding of IN. A). Transient knockdown of LEDGF/p75 by siRNA had no effect on IN
nuclear localization. 293T cells were transfected with either 20 nM negative control (NC) siRNA or 20 nM si-LEDGF PSIP1HSS146003 for 24 h
before transfection with CMV-YFP-IN wild type. At 48 h post-transfection, cells were fixed, permeabilized and detected for YFP-IN and LEDGF/p75
expression by using anti-GFP or anti-LEDGF antibodies. The nuclei were stained with DAPI. B). Analysis of chromatin binding affinity of IN on
LEDGF/p75 knockdown cells. The lentiviral shRNA-mediated LEDGF/p75 stable knockdown 293T cells were transfected with 20 nM si-LEDGF for
48 h and further transfected with YFP-IN wild type or mutant V165A and were analyzed for its chromatin binding affinity. In parallel, cells were
either mock-transfected or transfected with negative control siRNA to study chromatin binding of YFP-IN wild type. The chromatin bound and
non-chromatin-bound fractions of YFP-IN wild type or V165A were showed as indicated. The LEDGF/p75 expression level in each sample was
verified by WB with anti-LEDGF antibody. Endogenous beta-actin was used for normalization of sample loading.
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Page 10 of 14from chromatin. Furthermore, the single-round HIV-1
replication assay results showed that the viruses harbor-
ing IN mutants capable of LEDGF/p75-independent
chromatin binding still sustained a low level of infection.
All of these data indicate that while LEDGF/p75 is
important for productive HIV-1 replication, IN has the
ability to bind chromatin in a LEDGF/p75-independent
manner and sustain a low level HIV-1 infection.
The results showed that IN mutants K159P, A179P
and I203P located at the a-helices 4, 5 and 6 specifically
affected both chromatin- and LEDGF/p75-binding abil-
ities. Since introducing proline often bends the amino-
acid backbone and affects the secondary structure of the
protein, it could be possible that introducing proline
mutations disrupts a-helix formation and hampers both
chromatin- and LEDGF/p75-binding abilities. Indeed,
this could be the case for the IN mutant I203P because
another mutant I203A was able to efficiently bind host
DNA and LEDGF/p75 (Figs. 1 and 2 compare lane 14 to
15). However, given the fact that both A179P and A179I
lost binding to host chromatin, the A179 residue may
be directly involved in interacting with host chromatin
(Fig. 1 and data not shown for A179I). Nevertheless, the
chromatin-binding phenotype of K159P, A179P and
I203P IN mutants suggest the involvement of a-helices
4 ,5a n d6o fI Ni nh o s tD N Ar e c o g n i t i o n .T w oo t h e r
IN mutants that need to be addressed are KR186,7AA
and F185A. We have previously shown that the IN
mutant KR186,7AA was severely impaired in both chro-
matin- and LEDGF-binding affinities [24]. In this study,
we identified another mutant F185A that displayed a
significant reduction in the interaction with LEDGF and
chromatin, but to a lesser extent than that of
KR186,7AA. The K186 and R187 of IN, by crystallo-
graphic studies, are known to lie in the dimer-dimer
interface of IN [42,43] and F185 has been implicated for
tetramerization of IN [44]. So, mutations at F185, K186
and R187 might affect IN oligomerization and further
impair its chromatin binding affinity. In addition, a
recent study by Merad H et al. revealed that a helix-
turn-helix (HTH) (residues 149-186) motif consists of
two helices (helix 4 and helix 5) and that the loop in
between is involved in recognition of viral DNA [19].
Interestingly, in our study, IN mutants K159A, V165A,
V176A, A179P, KR186,7AA are located within this
region and were identified as chromatin-binding defec-
tive mutants. Thus, the chromosomal attachment site
within the IN CCD may also center on IN a-helix 4 to
a-helix 5, and this HTH motif could be critical for the
recognition of both viral and host DNA. However, how
IN recognizes and binds both viral and host DNA
sequence to form an active integration complex remains
an open question and requires more detailed computa-
tional, experimental and structural investigations.
However, the functional roles of LEDGF/p75 and its
potential correlation with chromatin binding of IN are
of interest in our present study. It is well established
that LEDGF/p75 serves as an IN-to-chromatin tethering
factor, driving PICs to transcriptionally active regions of
host chromosomes [5,14]. Our previous results showed
that chromatin binding defective IN mutants (V165A,
A179P, KR186,7AA) also fail to interact with LEDGF/
Figure 6 A) The differential replication profiles of IN mutant viruses within the loop 170EHLK173 on HIV-1 single-cycle replication. 293T
cells were co-transfected with an RT/IN/Env-deleted HIV-1 provirus NLlucΔBglΔRI, each CMV-Vpr-RT-IN (wt/mut) expressor and a VSV-G expressor
to generate single round replication competent virus. To test the effect of different IN mutant viruses on HIV-1 infection, C8166 T cells were
infected with equal amount of VSV-G pseudotyped IN mutant viruses (adjust by p24 level) for 48 h. 1 × 10
6 cells were collected and cell-
associated luciferase activity was measured by luciferase assay at 48 h post-infection. B) Followed by 12 h infection with single cycle replicating
viruses on dividing C8166 T cells, total DNA was extracted and amplified for total viral DNA and human b-globin gene using corresponding
primers by Real time PCR. Total HIV-1 DNA levels were expressed as copy numbers per cell, with DNA template normalized by the amplification
of the b-globin gene. NC: negative control or 70°C inactivated wt virus.
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Page 11 of 14p75, suggesting that LEDGF-binding of IN might be
linked to the chromatin-binding affinity of IN [24].
Here, we attempted to select more IN mutants to map
both chromatin- and LEDGF/p75-binding sites within
the CCD of IN. Results showed that most of the IN
mutants tested in this study lost both chromatin-binding
and LEDGF/p75-interacting abilities, highlighting the
importance of LEDGF/p75 as a tethering factor for IN
chromatin targeting. Interestingly, two IN mutants,
H171A and L172A within the CCD of IN, displayed a
different phenotype; they could not efficiently interact
with LEDGF/p75 yet still could bind chromatin (Fig. 1
and 2, see also Table 1). This raises the possibility that
the HIV-1 IN may still be able to target chromatin in
the absence of LEDGF/p75 association. Because H171
and L172 are located within or close to the loci of IN/
LEDGF interface (a4/5 connector residues 166-171) [9],
we next focused on detailed chromatin- and LEDGF-
binding affinities within the IN region 170EHLK173. For
this purpose, four IN double mutants, EH170,1AA,
EK170,3AA, HL171,2AA and HK171,3AA, were tested.
Indeed, it was shown again that the IN mutant
EH170,1AA showed relatively high affinity with host
chromatin but was unable to bind LEDGF/p75 effec-
tively, while the IN mutant HL171,2AA had defects on
both the chromatin- and LEDGF-binding affinities (Fig.
3). These results suggest that the HIV-1 IN is able to
bind chromatin independently of LEDGF/p75.
Because the IN mutants H171A, L172A and
EH170,1AA bound to chromatin but not LEDGF/p75,
we further reconfirmed the LEDGF/p75 independent
chromatin binding of wild type IN using the LEDGF/
p75-KD cells. Our results showed that the efficient
knockdown of LEDGF/p75 had no significant effect on
IN to chromatin-association, suggesting that the chro-
matin binding of IN might still take place in the absence
of LEDGF/p75. Meanwhile, we ruled out the possible
effect of LEDGF/p75 knockdown on nuclear transloca-
tion of HIV-1 with wild type IN by observing the intra-
cellular localization of all the IN fusion proteins using
immunostaining, which is indeed consistent with the
previous observation [13]. Most likely, the IN is still
able to target chromatin without preferential targeting
sites in the absence of LEDGF/p75. Consistently, pre-
vious studies have highlighted that the role of LEDGF/
p75 during HIV-1 integration is advantageous to HIV-1
integration but could be nonessential to the process of
integration [5,45]. We speculate that, without the
LEDGF/p75 tethering, IN might still be able to bind
chromatin, but it might lack the preferential selection
site. Also, it is possible that other unknown cellular fac-
tor(s) might contribute to the chromatin targeting of IN;
such proteins should harbor both DNA-binding and IN-
binding domains similar to that of LEDGF/p75. Further
efforts are underway to seek new cellular partners
involved in IN-to-chromatin targeting.
In an attempt to correlate IN chromatin-binding abil-
ity to its effect on virus infection, we introduced IN
mutants EH170,1AA, EK170,3AA or HL171,2AA into a
VSV-G pseudotyped HIV-1 single cycle replicating virus
and investigated their effects on HIV-1 infection. As
expected, viruses containing the IN HL171,2AA muta-
tion, which lost both LEDGF/p75- and chromatin-bind-
ing abilities, are unable to replicate (Fig. 6). This result
is consistent with previous reports in which the
impaired integration of proviral DNA into host cell
chromatin accounted for the replication defect of the
L172 mutant virus [46,47]. Interestingly, another batch
of viruses harboring the IN EH170,1AA mutation,
which fail to associate with LEDGF/p75 but are still able
to interact with chromatin, retain the infectivity towards
the susceptible cell lines, although at a low efficiency.
This suggests that the chromatin association of IN,
rather than LEDGF/p75 binding, is essential for HIV-1
infection. These results are consistent with the previous
study by Shun and his co-workers in which the LEDGF-
null mouse embryo fibroblasts were able to support
approximately 10% of HIV-1 integration compared to
control cells [40]. These results again highlighted the
importance of LEDGF/p75-binding property of IN dur-
ing HIV-1 replication. It is possible that the LEDGF-
independent chromatin binding of IN is still able to tar-
get viral PICs to host chromatin, but, without the escort
of LEDGF/p75, such IN-mediated “nonspecific” chroma-
tin binding is less efficient and/or could not efficiently
target viral PICs to transcriptionally active sites in the
chromatin and mediate a productive viral replication.
Another interesting question is how IN is still able to
interact with host chromatin under a very low level of
LEDGF/p75. Whether it is through IN directly binding
to host DNA or whether it requires other undefined
cofactor(s) for this process remains unclear and requires
more detailed study. Successful elucidation of the
mechanism underlying how HIV-1 IN possesses a
LEDGF/p75-independent chromatin binding and identi-
fication of other IN-interacting cofactors involved in
this process will contribute to a better understanding of
the action of IN during HIV-1 replication and aid in
development of efficient and comprehensive anti-HIV
strategies.
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